JP5727946B2 - Ｋｃｎｑ２／３モジュレータとしての置換された２−メルカプトキノリン−３−カルボキサミド - Google Patents
Ｋｃｎｑ２／３モジュレータとしての置換された２−メルカプトキノリン−３−カルボキサミド Download PDFInfo
- Publication number
- JP5727946B2 JP5727946B2 JP2011553352A JP2011553352A JP5727946B2 JP 5727946 B2 JP5727946 B2 JP 5727946B2 JP 2011553352 A JP2011553352 A JP 2011553352A JP 2011553352 A JP2011553352 A JP 2011553352A JP 5727946 B2 JP5727946 B2 JP 5727946B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- carboxamide
- quinoline
- ethylsulfanyl
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CKWKREFECQVBBZ-UHFFFAOYSA-N 2-sulfanylidene-1h-quinoline-3-carboxamide Chemical class C1=CC=C2N=C(S)C(C(=O)N)=CC2=C1 CKWKREFECQVBBZ-UHFFFAOYSA-N 0.000 title claims description 22
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 title description 17
- 102000005453 KCNQ2 Potassium Channel Human genes 0.000 title description 17
- 125000001424 substituent group Chemical group 0.000 claims description 121
- 229920006395 saturated elastomer Polymers 0.000 claims description 82
- 125000003118 aryl group Chemical group 0.000 claims description 70
- 125000001072 heteroaryl group Chemical group 0.000 claims description 65
- 125000000623 heterocyclic group Chemical group 0.000 claims description 59
- -1 heptanyl Chemical group 0.000 claims description 57
- 150000001875 compounds Chemical class 0.000 claims description 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 42
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 37
- 125000004076 pyridyl group Chemical group 0.000 claims description 32
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 30
- 208000002193 Pain Diseases 0.000 claims description 29
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 27
- 125000001544 thienyl group Chemical group 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 23
- 230000036407 pain Effects 0.000 claims description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 16
- NBCYYXBLHMLNDK-UHFFFAOYSA-N methyl 3-[3-(thiophen-2-ylmethylcarbamoyl)quinolin-2-yl]sulfanylpropanoate Chemical compound COC(=O)CCSC1=NC2=CC=CC=C2C=C1C(=O)NCC1=CC=CS1 NBCYYXBLHMLNDK-UHFFFAOYSA-N 0.000 claims description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 206010015037 epilepsy Diseases 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 8
- 206010046543 Urinary incontinence Diseases 0.000 claims description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 150000003857 carboxamides Chemical class 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- QHSCXJURDJMJFF-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(2-methoxyphenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC=C1OC QHSCXJURDJMJFF-UHFFFAOYSA-N 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 206010003591 Ataxia Diseases 0.000 claims description 5
- 206010026749 Mania Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 125000001624 naphthyl group Chemical class 0.000 claims description 5
- QSTRXYDQLKNNRG-UHFFFAOYSA-N 2-[2-(benzenesulfonyl)ethylsulfanyl]-n-(thiophen-2-ylmethyl)-6-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C=1C=CSC=1CNC(=O)C1=CC2=CC(C(F)(F)F)=CC=C2N=C1SCCS(=O)(=O)C1=CC=CC=C1 QSTRXYDQLKNNRG-UHFFFAOYSA-N 0.000 claims description 4
- RBTMWCQEJUGFEI-UHFFFAOYSA-N 2-[2-(benzenesulfonyl)ethylsulfanyl]-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound C=1C2=CC=CC=C2N=C(SCCS(=O)(=O)C=2C=CC=CC=2)C=1C(=O)NCC1=CC=CS1 RBTMWCQEJUGFEI-UHFFFAOYSA-N 0.000 claims description 4
- ZTLQZLGRVVKUAU-UHFFFAOYSA-N 2-ethylsulfanyl-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=CC=C2C=C1C(=O)NCC1=CC=CS1 ZTLQZLGRVVKUAU-UHFFFAOYSA-N 0.000 claims description 4
- BREOLMRUUXYWDE-UHFFFAOYSA-N 2-pentylsulfanyl-n-(thiophen-2-ylmethyl)-6-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCCCCSC1=NC2=CC=C(C(F)(F)F)C=C2C=C1C(=O)NCC1=CC=CS1 BREOLMRUUXYWDE-UHFFFAOYSA-N 0.000 claims description 4
- YDGBZUQDDHAFFQ-UHFFFAOYSA-N 2-pentylsulfanyl-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound CCCCCSC1=NC2=CC=CC=C2C=C1C(=O)NCC1=CC=CS1 YDGBZUQDDHAFFQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 206010012335 Dependence Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- KSJCXIFGVXTUQS-UHFFFAOYSA-N methyl 3-[3-(thiophen-2-ylmethylcarbamoyl)-6-(trifluoromethyl)quinolin-2-yl]sulfanylpropanoate Chemical compound COC(=O)CCSC1=NC2=CC=C(C(F)(F)F)C=C2C=C1C(=O)NCC1=CC=CS1 KSJCXIFGVXTUQS-UHFFFAOYSA-N 0.000 claims description 4
- NTTDUJUDUWYVHA-UHFFFAOYSA-N n-(thiophen-2-ylmethyl)-2-[2-[3-(trifluoromethyl)phenyl]sulfonylethylsulfanyl]quinoline-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)CCSC=2C(=CC3=CC=CC=C3N=2)C(=O)NCC=2SC=CC=2)=C1 NTTDUJUDUWYVHA-UHFFFAOYSA-N 0.000 claims description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- KXZSVYHFYHTNBI-UHFFFAOYSA-N 1h-quinoline-2-thione Chemical class C1=CC=CC2=NC(S)=CC=C21 KXZSVYHFYHTNBI-UHFFFAOYSA-N 0.000 claims description 2
- KGTWXLZUIRMNID-UHFFFAOYSA-N 2-(2-phenylsulfanylethylsulfanyl)-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound C=1C2=CC=CC=C2N=C(SCCSC=2C=CC=CC=2)C=1C(=O)NCC1=CC=CS1 KGTWXLZUIRMNID-UHFFFAOYSA-N 0.000 claims description 2
- BRDPCVBAVSHWJG-UHFFFAOYSA-N 2-(3-cyclohexylpropylsulfanyl)-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound C=1C2=CC=CC=C2N=C(SCCCC2CCCCC2)C=1C(=O)NCC1=CC=CS1 BRDPCVBAVSHWJG-UHFFFAOYSA-N 0.000 claims description 2
- DCPMSEUNUUZOKE-UHFFFAOYSA-N 2-(3-phenylpropylsulfanyl)-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound C=1C2=CC=CC=C2N=C(SCCCC=2C=CC=CC=2)C=1C(=O)NCC1=CC=CS1 DCPMSEUNUUZOKE-UHFFFAOYSA-N 0.000 claims description 2
- FIKGWBYHTKYKJN-UHFFFAOYSA-N 2-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C1=CC=C2N=C(C(F)(F)F)C(C(=O)N)=CC2=C1 FIKGWBYHTKYKJN-UHFFFAOYSA-N 0.000 claims description 2
- DKXNTGWJGKSAJN-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)sulfanylethylsulfanyl]-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound C1=CC(F)=CC=C1SCCSC1=NC2=CC=CC=C2C=C1C(=O)NCC1=CC=CS1 DKXNTGWJGKSAJN-UHFFFAOYSA-N 0.000 claims description 2
- LGLZFNXJLHWYLR-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)sulfonylethylsulfanyl]-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)CCSC1=NC2=CC=CC=C2C=C1C(=O)NCC1=CC=CS1 LGLZFNXJLHWYLR-UHFFFAOYSA-N 0.000 claims description 2
- XNTODQLICDNQKF-UHFFFAOYSA-N 2-[2-(4-methylphenyl)sulfanylethylsulfanyl]-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound C1=CC(C)=CC=C1SCCSC1=NC2=CC=CC=C2C=C1C(=O)NCC1=CC=CS1 XNTODQLICDNQKF-UHFFFAOYSA-N 0.000 claims description 2
- VZFKPENHJUZZDW-UHFFFAOYSA-N 2-[2-(4-methylphenyl)sulfonylethylsulfanyl]-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)CCSC1=NC2=CC=CC=C2C=C1C(=O)NCC1=CC=CS1 VZFKPENHJUZZDW-UHFFFAOYSA-N 0.000 claims description 2
- KNVVYVSPKSXKSE-UHFFFAOYSA-N 2-[2-(benzenesulfonyl)ethylsulfanyl]-n-(2-cyclohexylethyl)quinoline-3-carboxamide Chemical compound C=1C2=CC=CC=C2N=C(SCCS(=O)(=O)C=2C=CC=CC=2)C=1C(=O)NCCC1CCCCC1 KNVVYVSPKSXKSE-UHFFFAOYSA-N 0.000 claims description 2
- IXAZYBWMTOQTNB-UHFFFAOYSA-N 2-[2-(benzenesulfonyl)ethylsulfanyl]-n-(3,3-dimethylbutyl)quinoline-3-carboxamide Chemical compound CC(C)(C)CCNC(=O)C1=CC2=CC=CC=C2N=C1SCCS(=O)(=O)C1=CC=CC=C1 IXAZYBWMTOQTNB-UHFFFAOYSA-N 0.000 claims description 2
- ICECDKYGZLCPCK-UHFFFAOYSA-N 2-[2-(benzenesulfonyl)ethylsulfanyl]-n-(cyclohexylmethyl)quinoline-3-carboxamide Chemical compound C=1C2=CC=CC=C2N=C(SCCS(=O)(=O)C=2C=CC=CC=2)C=1C(=O)NCC1CCCCC1 ICECDKYGZLCPCK-UHFFFAOYSA-N 0.000 claims description 2
- WAUDLZDKCYBPFH-UHFFFAOYSA-N 2-[2-(benzenesulfonyl)ethylsulfanyl]-n-(thiophen-2-ylmethyl)-5-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C=1C=CSC=1CNC(=O)C=1C=C2C(C(F)(F)F)=CC=CC2=NC=1SCCS(=O)(=O)C1=CC=CC=C1 WAUDLZDKCYBPFH-UHFFFAOYSA-N 0.000 claims description 2
- IDAUDNJJPNYANF-UHFFFAOYSA-N 2-[2-(benzenesulfonyl)ethylsulfanyl]-n-(thiophen-2-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C=1C=CC=CC=1S(=O)(=O)CCSC1=NC2=CC(C(F)(F)F)=CC=C2C=C1C(=O)NCC1=CC=CS1 IDAUDNJJPNYANF-UHFFFAOYSA-N 0.000 claims description 2
- SVTHLGYCZILPPE-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)propylsulfanyl]-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound C1=CC(F)=CC=C1CCCSC1=NC2=CC=CC=C2C=C1C(=O)NCC1=CC=CS1 SVTHLGYCZILPPE-UHFFFAOYSA-N 0.000 claims description 2
- CAMGJASCBPTCFP-UHFFFAOYSA-N 2-[3-(4-methylphenyl)propylsulfanyl]-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound C1=CC(C)=CC=C1CCCSC1=NC2=CC=CC=C2C=C1C(=O)NCC1=CC=CS1 CAMGJASCBPTCFP-UHFFFAOYSA-N 0.000 claims description 2
- VRQWABCZGRMEQJ-UHFFFAOYSA-N 2-butan-2-ylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCC(C)SC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 VRQWABCZGRMEQJ-UHFFFAOYSA-N 0.000 claims description 2
- DJHVPBBAOXXVAQ-UHFFFAOYSA-N 2-cyclohexylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C1CCCCC1SC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 DJHVPBBAOXXVAQ-UHFFFAOYSA-N 0.000 claims description 2
- HRZPDVLZIHPYIZ-UHFFFAOYSA-N 2-cyclopentylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C1CCCC1SC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 HRZPDVLZIHPYIZ-UHFFFAOYSA-N 0.000 claims description 2
- TWWCMRROISPVRQ-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)-n-[(2,4,5-trifluorophenyl)methyl]quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC(F)=C(F)C=C1F TWWCMRROISPVRQ-UHFFFAOYSA-N 0.000 claims description 2
- RGAFQVDDHODCOV-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)-n-[[4-(trifluoromethyl)phenyl]methyl]quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(C(F)(F)F)C=C1 RGAFQVDDHODCOV-UHFFFAOYSA-N 0.000 claims description 2
- FBCCCXHQDZEHAC-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(1,3-thiazol-2-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=NC=CS1 FBCCCXHQDZEHAC-UHFFFAOYSA-N 0.000 claims description 2
- XUGHLZBAJAZKQZ-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(2-phenylethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCCC1=CC=CC=C1 XUGHLZBAJAZKQZ-UHFFFAOYSA-N 0.000 claims description 2
- CSFVPXMKBCZQBY-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(3-methylbutyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound FC(F)(F)C1=CC=C2C(C)=C(C(=O)NCCC(C)C)C(SCC)=NC2=C1 CSFVPXMKBCZQBY-UHFFFAOYSA-N 0.000 claims description 2
- KZGVSMQUEAHERR-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(3-phenylpropyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCCCC1=CC=CC=C1 KZGVSMQUEAHERR-UHFFFAOYSA-N 0.000 claims description 2
- MWGVUZKBKRYEKP-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(4-methylpentyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound FC(F)(F)C1=CC=C2C(C)=C(C(=O)NCCCC(C)C)C(SCC)=NC2=C1 MWGVUZKBKRYEKP-UHFFFAOYSA-N 0.000 claims description 2
- YZELSMCHGJYNQE-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(naphthalen-2-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(CNC(=O)C3=C(C)C4=CC=C(C=C4N=C3SCC)C(F)(F)F)=CC=C21 YZELSMCHGJYNQE-UHFFFAOYSA-N 0.000 claims description 2
- JVVRXTXGGYVPAJ-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(oxan-2-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1CCCCO1 JVVRXTXGGYVPAJ-UHFFFAOYSA-N 0.000 claims description 2
- ZXWBBKUQWALZRY-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(pyridin-3-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CN=C1 ZXWBBKUQWALZRY-UHFFFAOYSA-N 0.000 claims description 2
- WJVVKGGHLHKRFE-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(pyridin-4-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=NC=C1 WJVVKGGHLHKRFE-UHFFFAOYSA-N 0.000 claims description 2
- AYYXMMBTPXLNMB-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=CC=C2C(C)=C1C(=O)NCC1=CC=CS1 AYYXMMBTPXLNMB-UHFFFAOYSA-N 0.000 claims description 2
- SFNWNEULSOKQDG-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-[(2-methylphenyl)methyl]-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC=C1C SFNWNEULSOKQDG-UHFFFAOYSA-N 0.000 claims description 2
- NCTJTIHXQVHHTQ-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-[(4-methylphenyl)methyl]-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(C)C=C1 NCTJTIHXQVHHTQ-UHFFFAOYSA-N 0.000 claims description 2
- FVLUNDJABKIFLB-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-[(4-methylthiophen-2-yl)methyl]-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC(C)=CS1 FVLUNDJABKIFLB-UHFFFAOYSA-N 0.000 claims description 2
- BPZASLDQFMWJDE-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-[(5-methylfuran-2-yl)methyl]-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(C)O1 BPZASLDQFMWJDE-UHFFFAOYSA-N 0.000 claims description 2
- MESBCMXZDOPINP-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-[(5-methylthiophen-2-yl)methyl]-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(C)S1 MESBCMXZDOPINP-UHFFFAOYSA-N 0.000 claims description 2
- BQUSIWROFGNJHZ-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-propyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C1=C(C(F)(F)F)C=C2N=C(SCC)C(C(=O)NCCC)=C(C)C2=C1 BQUSIWROFGNJHZ-UHFFFAOYSA-N 0.000 claims description 2
- FVZVRJDBPYZXNJ-UHFFFAOYSA-N 2-ethylsulfanyl-5-fluoro-n-[(3-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=CC(F)=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 FVZVRJDBPYZXNJ-UHFFFAOYSA-N 0.000 claims description 2
- INILATDIIGNRRP-UHFFFAOYSA-N 2-ethylsulfanyl-5-fluoro-n-[(4-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=CC(F)=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 INILATDIIGNRRP-UHFFFAOYSA-N 0.000 claims description 2
- XAJZZLZZOGAEOE-UHFFFAOYSA-N 2-ethylsulfanyl-6,7-difluoro-n-[(3-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(F)=C(F)C=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 XAJZZLZZOGAEOE-UHFFFAOYSA-N 0.000 claims description 2
- KDYVECDQZBNVNN-UHFFFAOYSA-N 2-ethylsulfanyl-6,7-difluoro-n-[(4-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(F)=C(F)C=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 KDYVECDQZBNVNN-UHFFFAOYSA-N 0.000 claims description 2
- NDQQAANSMNSKGC-UHFFFAOYSA-N 2-ethylsulfanyl-6-fluoro-n-[(3-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=C(F)C=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 NDQQAANSMNSKGC-UHFFFAOYSA-N 0.000 claims description 2
- LABJBBGATZAEOJ-UHFFFAOYSA-N 2-ethylsulfanyl-6-fluoro-n-[(4-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=C(F)C=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 LABJBBGATZAEOJ-UHFFFAOYSA-N 0.000 claims description 2
- KENKFKUDCKSCJA-UHFFFAOYSA-N 2-ethylsulfanyl-7-fluoro-n-[(4-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 KENKFKUDCKSCJA-UHFFFAOYSA-N 0.000 claims description 2
- NDJCIULEZPSLRB-UHFFFAOYSA-N 2-ethylsulfanyl-8-fluoro-n-[(3-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=C(F)C=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 NDJCIULEZPSLRB-UHFFFAOYSA-N 0.000 claims description 2
- KDBBRFBPEGZGHV-UHFFFAOYSA-N 2-ethylsulfanyl-8-fluoro-n-[(4-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=C(F)C=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 KDBBRFBPEGZGHV-UHFFFAOYSA-N 0.000 claims description 2
- OHILXZYXWBTIAZ-UHFFFAOYSA-N 2-ethylsulfanyl-N-[(3-fluorophenyl)methyl]-5-hydroxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=CC(O)=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 OHILXZYXWBTIAZ-UHFFFAOYSA-N 0.000 claims description 2
- RSHAXOBQFNTNFZ-UHFFFAOYSA-N 2-ethylsulfanyl-N-[(3-fluorophenyl)methyl]-7-hydroxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(O)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 RSHAXOBQFNTNFZ-UHFFFAOYSA-N 0.000 claims description 2
- SXOOLPIAGGAHHO-UHFFFAOYSA-N 2-ethylsulfanyl-n-(2-methoxyethyl)-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound FC(F)(F)C1=CC=C2C(C)=C(C(=O)NCCOC)C(SCC)=NC2=C1 SXOOLPIAGGAHHO-UHFFFAOYSA-N 0.000 claims description 2
- JNDKOXNXROGEGL-UHFFFAOYSA-N 2-ethylsulfanyl-n-(furan-2-ylmethyl)-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CO1 JNDKOXNXROGEGL-UHFFFAOYSA-N 0.000 claims description 2
- LLQWDECGIBUBSA-UHFFFAOYSA-N 2-ethylsulfanyl-n-(thiophen-2-ylmethyl)-6-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=C(C(F)(F)F)C=C2C=C1C(=O)NCC1=CC=CS1 LLQWDECGIBUBSA-UHFFFAOYSA-N 0.000 claims description 2
- HWHHEFYPKKESMJ-UHFFFAOYSA-N 2-ethylsulfanyl-n-(thiophen-2-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C=C1C(=O)NCC1=CC=CS1 HWHHEFYPKKESMJ-UHFFFAOYSA-N 0.000 claims description 2
- CVPNKHGHUHYXSF-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(2-fluorophenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC=C1F CVPNKHGHUHYXSF-UHFFFAOYSA-N 0.000 claims description 2
- JDWVPVJGBLRMSB-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluoro-2-methoxyphenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1OC JDWVPVJGBLRMSB-UHFFFAOYSA-N 0.000 claims description 2
- VPEQAVSFITWFAB-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4,6-dimethylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=C(C)C=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 VPEQAVSFITWFAB-UHFFFAOYSA-N 0.000 claims description 2
- FLOGQWJVRCMVLX-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4,7-dimethylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 FLOGQWJVRCMVLX-UHFFFAOYSA-N 0.000 claims description 2
- NVUWBSSYAVGYIH-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-7-(trifluoromethoxy)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(OC(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 NVUWBSSYAVGYIH-UHFFFAOYSA-N 0.000 claims description 2
- MJFLPXIKFLITQN-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 MJFLPXIKFLITQN-UHFFFAOYSA-N 0.000 claims description 2
- LYZQVGDGPNDVQB-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-7-morpholin-4-ylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(N3CCOCC3)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 LYZQVGDGPNDVQB-UHFFFAOYSA-N 0.000 claims description 2
- MZIPSMYUYFBNCR-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-8-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=C(C(F)(F)F)C=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 MZIPSMYUYFBNCR-UHFFFAOYSA-N 0.000 claims description 2
- ZADBLFFTGRNBGB-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 ZADBLFFTGRNBGB-UHFFFAOYSA-N 0.000 claims description 2
- IHZJRRYQQOKLHZ-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-6-hydroxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=C(O)C=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 IHZJRRYQQOKLHZ-UHFFFAOYSA-N 0.000 claims description 2
- WAMWQSYOLZGPPC-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-6-methoxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=C(OC)C=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 WAMWQSYOLZGPPC-UHFFFAOYSA-N 0.000 claims description 2
- KYGXDUGKSUSASJ-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-7-methoxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(OC)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 KYGXDUGKSUSASJ-UHFFFAOYSA-N 0.000 claims description 2
- YOWNRDGWKVDGQH-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-8-hydroxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=C(O)C=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 YOWNRDGWKVDGQH-UHFFFAOYSA-N 0.000 claims description 2
- UASHZJNTJBWTMU-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-8-methoxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=C(OC)C=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 UASHZJNTJBWTMU-UHFFFAOYSA-N 0.000 claims description 2
- LSYYRADNMXOUCS-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-hydroxyphenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(O)=C1 LSYYRADNMXOUCS-UHFFFAOYSA-N 0.000 claims description 2
- FBKKIWULZDMVQH-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-methoxyphenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(OC)=C1 FBKKIWULZDMVQH-UHFFFAOYSA-N 0.000 claims description 2
- FMLZFYMQFQIECC-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-4,6-dimethylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=C(C)C=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 FMLZFYMQFQIECC-UHFFFAOYSA-N 0.000 claims description 2
- CJPHPQSCJRMVRG-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-4,7-dimethylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 CJPHPQSCJRMVRG-UHFFFAOYSA-N 0.000 claims description 2
- SAWIMBMEOKWHTK-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-4-methyl-6-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=C(C(F)(F)F)C=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 SAWIMBMEOKWHTK-UHFFFAOYSA-N 0.000 claims description 2
- SOYJZGNVWTYSPM-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-4-methyl-7-morpholin-4-ylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(N3CCOCC3)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 SOYJZGNVWTYSPM-UHFFFAOYSA-N 0.000 claims description 2
- RFYJQTJSTFMILH-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-4-methyl-8-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=C(C(F)(F)F)C=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 RFYJQTJSTFMILH-UHFFFAOYSA-N 0.000 claims description 2
- MPUAMENIGDRSCH-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-5-methoxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=CC(OC)=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 MPUAMENIGDRSCH-UHFFFAOYSA-N 0.000 claims description 2
- ZYTRDNHAJLVSMB-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-6-methoxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=C(OC)C=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 ZYTRDNHAJLVSMB-UHFFFAOYSA-N 0.000 claims description 2
- FCKWQKABEZLSIZ-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-7-methoxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(OC)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 FCKWQKABEZLSIZ-UHFFFAOYSA-N 0.000 claims description 2
- ODOGGYIXTMHZTB-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-8-methoxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=C(OC)C=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 ODOGGYIXTMHZTB-UHFFFAOYSA-N 0.000 claims description 2
- CYKHHMRMKNWUID-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-hydroxyphenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(O)C=C1 CYKHHMRMKNWUID-UHFFFAOYSA-N 0.000 claims description 2
- KFFNMVZGDLTROQ-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-methoxyphenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(OC)C=C1 KFFNMVZGDLTROQ-UHFFFAOYSA-N 0.000 claims description 2
- FWEGXRYDFLZWBI-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(5-fluoro-2-methoxyphenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC(F)=CC=C1OC FWEGXRYDFLZWBI-UHFFFAOYSA-N 0.000 claims description 2
- YFFOIBIFJQYVIE-UHFFFAOYSA-N 2-pentylsulfanyl-n-(thiophen-2-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCCCCSC1=NC2=CC(C(F)(F)F)=CC=C2C=C1C(=O)NCC1=CC=CS1 YFFOIBIFJQYVIE-UHFFFAOYSA-N 0.000 claims description 2
- XXAIJBJYRVSQTA-UHFFFAOYSA-N 2-tert-butylsulfanyl-4-methyl-n-(thiophen-2-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CC(C)(C)SC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CS1 XXAIJBJYRVSQTA-UHFFFAOYSA-N 0.000 claims description 2
- SIGLDVRDMZLGMM-UHFFFAOYSA-N 2-tert-butylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CC(C)(C)SC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 SIGLDVRDMZLGMM-UHFFFAOYSA-N 0.000 claims description 2
- NDXGLPCHCPPXFM-UHFFFAOYSA-N 2-tert-butylsulfanyl-n-[(4-fluorophenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CC(C)(C)SC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 NDXGLPCHCPPXFM-UHFFFAOYSA-N 0.000 claims description 2
- RGVSETOUKURHPQ-UHFFFAOYSA-N 4-ethyl-2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(CC)=C1C(=O)NCC1=CC=CC(F)=C1 RGVSETOUKURHPQ-UHFFFAOYSA-N 0.000 claims description 2
- QNOOPPFRMZZDCK-UHFFFAOYSA-N 4-methyl-2-methylsulfanyl-n-(thiophen-2-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CS1 QNOOPPFRMZZDCK-UHFFFAOYSA-N 0.000 claims description 2
- JKNRQZVJDVIZFW-UHFFFAOYSA-N 7-(dimethylamino)-2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(N(C)C)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 JKNRQZVJDVIZFW-UHFFFAOYSA-N 0.000 claims description 2
- OOSNPWMGMMQJEG-UHFFFAOYSA-N 7-tert-butyl-2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(C)(C)C)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 OOSNPWMGMMQJEG-UHFFFAOYSA-N 0.000 claims description 2
- UQISPJQRUAFUMF-UHFFFAOYSA-N 7-tert-butyl-2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(C)(C)C)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 UQISPJQRUAFUMF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- QTHJKBHMOIKBMN-UHFFFAOYSA-N methyl 3-[3-(thiophen-2-ylmethylcarbamoyl)-7-(trifluoromethyl)quinolin-2-yl]sulfanylpropanoate Chemical compound COC(=O)CCSC1=NC2=CC(C(F)(F)F)=CC=C2C=C1C(=O)NCC1=CC=CS1 QTHJKBHMOIKBMN-UHFFFAOYSA-N 0.000 claims description 2
- QQBAWMYFMOCPJS-UHFFFAOYSA-N n-(2,2-dimethylpropyl)-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound FC(F)(F)C1=CC=C2C(C)=C(C(=O)NCC(C)(C)C)C(SCC)=NC2=C1 QQBAWMYFMOCPJS-UHFFFAOYSA-N 0.000 claims description 2
- CTFLARWHTUMYPR-UHFFFAOYSA-N n-(2,2-dimethylpropyl)-2-ethylsulfanyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound FC(F)(F)C1=CC=C2C=C(C(=O)NCC(C)(C)C)C(SCC)=NC2=C1 CTFLARWHTUMYPR-UHFFFAOYSA-N 0.000 claims description 2
- ZVXKQFPIMUKOMT-UHFFFAOYSA-N n-(3,3-dimethylbutyl)-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound FC(F)(F)C1=CC=C2C(C)=C(C(=O)NCCC(C)(C)C)C(SCC)=NC2=C1 ZVXKQFPIMUKOMT-UHFFFAOYSA-N 0.000 claims description 2
- LFMCKLOLUWSBLS-UHFFFAOYSA-N n-(3-bicyclo[2.2.1]heptanylmethyl)-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound FC(F)(F)C1=CC=C2C(C)=C(C(=O)NCC3C4CCC(C4)C3)C(SCC)=NC2=C1 LFMCKLOLUWSBLS-UHFFFAOYSA-N 0.000 claims description 2
- ITNKYIXJOGYUKZ-UHFFFAOYSA-N n-(3-cyclopentylpropyl)-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCCCC1CCCC1 ITNKYIXJOGYUKZ-UHFFFAOYSA-N 0.000 claims description 2
- UXOOMLDNCNTUPT-UHFFFAOYSA-N n-(cycloheptylmethyl)-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1CCCCCC1 UXOOMLDNCNTUPT-UHFFFAOYSA-N 0.000 claims description 2
- DREYSSCBZYWDKN-UHFFFAOYSA-N n-(cyclohexylmethyl)-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1CCCCC1 DREYSSCBZYWDKN-UHFFFAOYSA-N 0.000 claims description 2
- LFPNCEAJPXGNML-UHFFFAOYSA-N n-[(2,4-difluorophenyl)methyl]-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1F LFPNCEAJPXGNML-UHFFFAOYSA-N 0.000 claims description 2
- SXIXGZAUGBMXJG-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC=C1Cl SXIXGZAUGBMXJG-UHFFFAOYSA-N 0.000 claims description 2
- WETDJQZLZCAQGP-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C(F)=C1 WETDJQZLZCAQGP-UHFFFAOYSA-N 0.000 claims description 2
- IPMGTBLKWNBMDC-UHFFFAOYSA-N n-[(3,4-dimethylphenyl)methyl]-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(C)C(C)=C1 IPMGTBLKWNBMDC-UHFFFAOYSA-N 0.000 claims description 2
- WQGLUAWWYMAZND-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC(F)=CC(F)=C1 WQGLUAWWYMAZND-UHFFFAOYSA-N 0.000 claims description 2
- ZWTYRXYXZVZVQH-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(Cl)=C1 ZWTYRXYXZVZVQH-UHFFFAOYSA-N 0.000 claims description 2
- AEMAXKFPWYKBIN-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-2-pentylsulfanyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCCCCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 AEMAXKFPWYKBIN-UHFFFAOYSA-N 0.000 claims description 2
- ZYEQTSLZKCAUET-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-2-propan-2-ylsulfanyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CC(C)SC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 ZYEQTSLZKCAUET-UHFFFAOYSA-N 0.000 claims description 2
- XLPZXRRXTSPHMD-UHFFFAOYSA-N n-[(3-tert-butylphenyl)methyl]-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(C(C)(C)C)=C1 XLPZXRRXTSPHMD-UHFFFAOYSA-N 0.000 claims description 2
- WDLWYVILARBQGH-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 WDLWYVILARBQGH-UHFFFAOYSA-N 0.000 claims description 2
- GIIHJIRAQCRSSB-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-methyl-2-methylsulfanyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 GIIHJIRAQCRSSB-UHFFFAOYSA-N 0.000 claims description 2
- AUTPBQFCUQZVKU-UHFFFAOYSA-N n-[(4-tert-butylphenyl)methyl]-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(C(C)(C)C)C=C1 AUTPBQFCUQZVKU-UHFFFAOYSA-N 0.000 claims description 2
- QDWNPQYMTVSWQT-UHFFFAOYSA-N n-benzyl-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC=C1 QDWNPQYMTVSWQT-UHFFFAOYSA-N 0.000 claims description 2
- PBLRPZQSTMLCET-UHFFFAOYSA-N n-butyl-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C1=C(C(F)(F)F)C=C2N=C(SCC)C(C(=O)NCCCC)=C(C)C2=C1 PBLRPZQSTMLCET-UHFFFAOYSA-N 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- JWWSIJYBINTJOV-UHFFFAOYSA-N 2-benzylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C=1C=CC=CC=1CSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 JWWSIJYBINTJOV-UHFFFAOYSA-N 0.000 claims 1
- GJZRTERWIGITRR-UHFFFAOYSA-N 2-butylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCCCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 GJZRTERWIGITRR-UHFFFAOYSA-N 0.000 claims 1
- JEIFVPVLNYRPCS-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)-n-[(3,4,5-trifluorophenyl)methyl]quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC(F)=C(F)C(F)=C1 JEIFVPVLNYRPCS-UHFFFAOYSA-N 0.000 claims 1
- JHCSBJAEVLXSGL-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)-n-[[4-(trifluoromethylsulfanyl)phenyl]methyl]quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(SC(F)(F)F)C=C1 JHCSBJAEVLXSGL-UHFFFAOYSA-N 0.000 claims 1
- UPGUNHZWSKRQTC-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(2-thiophen-2-ylethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCCC1=CC=CS1 UPGUNHZWSKRQTC-UHFFFAOYSA-N 0.000 claims 1
- FNBFBAAXYARCLB-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(pyridin-2-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC=N1 FNBFBAAXYARCLB-UHFFFAOYSA-N 0.000 claims 1
- BHCUNBSVUBPQHJ-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-[(3-methylphenyl)methyl]-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(C)=C1 BHCUNBSVUBPQHJ-UHFFFAOYSA-N 0.000 claims 1
- QWGINHANBPWPEJ-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-pentyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound C1=C(C(F)(F)F)C=C2N=C(SCC)C(C(=O)NCCCCC)=C(C)C2=C1 QWGINHANBPWPEJ-UHFFFAOYSA-N 0.000 claims 1
- ITWBLZUNBRFTGO-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-6-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=C(C(F)(F)F)C=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 ITWBLZUNBRFTGO-UHFFFAOYSA-N 0.000 claims 1
- HETGBONULOBHRC-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-propan-2-yl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C(C)C)=C1C(=O)NCC1=CC=CC(F)=C1 HETGBONULOBHRC-UHFFFAOYSA-N 0.000 claims 1
- KYNNNAWCIPIVEG-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-5-methoxy-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC=CC(OC)=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 KYNNNAWCIPIVEG-UHFFFAOYSA-N 0.000 claims 1
- BOQBDAUMFYRBFM-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 BOQBDAUMFYRBFM-UHFFFAOYSA-N 0.000 claims 1
- YCPDDSMWVVFPJV-UHFFFAOYSA-N 7-(dimethylamino)-2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(N(C)C)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 YCPDDSMWVVFPJV-UHFFFAOYSA-N 0.000 claims 1
- TVZMBAXSWJWZQW-UHFFFAOYSA-N n-(2-cyclopentylethyl)-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCCC1CCCC1 TVZMBAXSWJWZQW-UHFFFAOYSA-N 0.000 claims 1
- UMJKLILZNLGSPJ-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-2-methylsulfanyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 UMJKLILZNLGSPJ-UHFFFAOYSA-N 0.000 claims 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 66
- 239000000243 solution Substances 0.000 description 51
- 230000015572 biosynthetic process Effects 0.000 description 50
- 238000003786 synthesis reaction Methods 0.000 description 50
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- 125000000217 alkyl group Chemical group 0.000 description 33
- 239000012074 organic phase Substances 0.000 description 31
- 229910052799 carbon Inorganic materials 0.000 description 28
- 229910052760 oxygen Inorganic materials 0.000 description 28
- 239000011734 sodium Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000012267 brine Substances 0.000 description 27
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- 125000000753 cycloalkyl group Chemical group 0.000 description 25
- 125000004404 heteroalkyl group Chemical group 0.000 description 25
- 238000000034 method Methods 0.000 description 23
- 125000005842 heteroatom Chemical group 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000013067 intermediate product Substances 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 239000002585 base Substances 0.000 description 17
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 150000003573 thiols Chemical class 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000002243 precursor Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 108091006146 Channels Proteins 0.000 description 10
- 208000004296 neuralgia Diseases 0.000 description 10
- 208000021722 neuropathic pain Diseases 0.000 description 10
- 125000006413 ring segment Chemical group 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 208000000094 Chronic Pain Diseases 0.000 description 9
- 206010065390 Inflammatory pain Diseases 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 9
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 150000003568 thioethers Chemical class 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 208000000112 Myalgia Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- DCJNMGWPDQOJQB-UHFFFAOYSA-N 4-chloro-2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(Cl)=C1C(=O)NCC1=CC=CC(F)=C1 DCJNMGWPDQOJQB-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- BSGODBGMKHLYQS-UHFFFAOYSA-N 2-chloro-n-(thiophen-2-ylmethyl)quinoline-3-carboxamide Chemical compound ClC1=NC2=CC=CC=C2C=C1C(=O)NCC1=CC=CS1 BSGODBGMKHLYQS-UHFFFAOYSA-N 0.000 description 5
- 206010001497 Agitation Diseases 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 5
- 125000003386 piperidinyl group Chemical group 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- ZNNFRTKDYCOHHG-UHFFFAOYSA-N 2-chloro-n-[(3-fluorophenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound ClC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 ZNNFRTKDYCOHHG-UHFFFAOYSA-N 0.000 description 4
- IUTQYLGEHVTACZ-UHFFFAOYSA-N 2-ethylsulfanyl-6,7-difluoro-4-methylquinoline-3-carboxylic acid Chemical compound FC1=C(F)C=C2C(C)=C(C(O)=O)C(SCC)=NC2=C1 IUTQYLGEHVTACZ-UHFFFAOYSA-N 0.000 description 4
- PKAHUUWQTYKETK-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-oxo-7-(trifluoromethyl)-1h-quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(O)=C1C(=O)NCC1=CC=CC(F)=C1 PKAHUUWQTYKETK-UHFFFAOYSA-N 0.000 description 4
- RROHLYGILAONKK-UHFFFAOYSA-N 2-sulfanylidene-n-(thiophen-2-ylmethyl)-1h-quinoline-3-carboxamide Chemical compound SC1=NC2=CC=CC=C2C=C1C(=O)NCC1=CC=CS1 RROHLYGILAONKK-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 3
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010011185 KCNQ1 Potassium Channel Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102100037444 Potassium voltage-gated channel subfamily KQT member 1 Human genes 0.000 description 3
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- LVQIABILMXHRNR-UHFFFAOYSA-N ethyl 2-(3-ethoxy-3-oxopropyl)sulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxylate Chemical compound FC(F)(F)C1=CC=C2C(C)=C(C(=O)OCC)C(SCCC(=O)OCC)=NC2=C1 LVQIABILMXHRNR-UHFFFAOYSA-N 0.000 description 3
- DIEHOORTKYHMAJ-UHFFFAOYSA-N ethyl 7-(dimethylamino)-2-ethylsulfanyl-4-methylquinoline-3-carboxylate Chemical compound C1=C(N(C)C)C=C2N=C(SCC)C(C(=O)OCC)=C(C)C2=C1 DIEHOORTKYHMAJ-UHFFFAOYSA-N 0.000 description 3
- GHTIYADYAZRUJH-UHFFFAOYSA-N ethyl 7-tert-butyl-2-chloro-4-methylquinoline-3-carboxylate Chemical compound C1=C(C(C)(C)C)C=CC2=C(C)C(C(=O)OCC)=C(Cl)N=C21 GHTIYADYAZRUJH-UHFFFAOYSA-N 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002779 membrane potential assay Methods 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical class 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- BLXSFCHWMBESKV-UHFFFAOYSA-N 1-iodopentane Chemical compound CCCCCI BLXSFCHWMBESKV-UHFFFAOYSA-N 0.000 description 2
- BAEOVAZDSZHOSW-UHFFFAOYSA-N 2-(benzenesulfonyl)ethanethiol Chemical compound SCCS(=O)(=O)C1=CC=CC=C1 BAEOVAZDSZHOSW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- VJNKJMNBPRELJA-UHFFFAOYSA-N 2-[2-(benzenesulfonyl)ethylsulfanyl]-6-(trifluoromethyl)quinoline-3-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(C(F)(F)F)=CC=C2N=C1SCCS(=O)(=O)C1=CC=CC=C1 VJNKJMNBPRELJA-UHFFFAOYSA-N 0.000 description 2
- LGWGAGTUMHUNFJ-UHFFFAOYSA-N 2-chloro-6-(trifluoromethyl)quinoline-3-carboxylic acid Chemical compound FC(F)(F)C1=CC=C2N=C(Cl)C(C(=O)O)=CC2=C1 LGWGAGTUMHUNFJ-UHFFFAOYSA-N 0.000 description 2
- TWWIQRUZRONSAV-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxylic acid Chemical compound FC(F)(F)C1=CC=C2C(C)=C(C(O)=O)C(SCC)=NC2=C1 TWWIQRUZRONSAV-UHFFFAOYSA-N 0.000 description 2
- BAZMWIOACYAUFK-UHFFFAOYSA-N 2-ethylsulfanyl-4-methyl-n-(thiophen-2-ylmethyl)-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CS1 BAZMWIOACYAUFK-UHFFFAOYSA-N 0.000 description 2
- CCMZVZNUBUGZIF-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(2-hydroxyphenyl)methyl]-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC=C1O CCMZVZNUBUGZIF-UHFFFAOYSA-N 0.000 description 2
- GLCIGUSHMGITJY-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methoxy-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(OC)=C1C(=O)NCC1=CC=CC(F)=C1 GLCIGUSHMGITJY-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- WSRRQYJDESGPOK-UHFFFAOYSA-N 7-tert-butyl-2-ethylsulfanyl-4-methylquinoline-3-carboxylic acid Chemical compound CC(C)(C)C1=CC=C2C(C)=C(C(O)=O)C(SCC)=NC2=C1 WSRRQYJDESGPOK-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000994667 Homo sapiens Potassium voltage-gated channel subfamily KQT member 2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010076089 accutase Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 230000003502 anti-nociceptive effect Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- PYWGJAAWHGXMDP-UHFFFAOYSA-N ethyl 2-chloro-4-methyl-7-(trifluoromethyl)quinoline-3-carboxylate Chemical compound C1=C(C(F)(F)F)C=CC2=C(C)C(C(=O)OCC)=C(Cl)N=C21 PYWGJAAWHGXMDP-UHFFFAOYSA-N 0.000 description 2
- MEQIPWOQDKXCCD-UHFFFAOYSA-N ethyl 2-ethylsulfanyl-4-oxo-7-(trifluoromethyl)-1h-quinoline-3-carboxylate Chemical compound C1=C(C(F)(F)F)C=C2N=C(SCC)C(C(=O)OCC)=C(O)C2=C1 MEQIPWOQDKXCCD-UHFFFAOYSA-N 0.000 description 2
- NQCCMQSNXGPGQJ-UHFFFAOYSA-N ethyl 2-ethylsulfanyl-6,7-difluoro-4-methylquinoline-3-carboxylate Chemical compound FC1=C(F)C=C2N=C(SCC)C(C(=O)OCC)=C(C)C2=C1 NQCCMQSNXGPGQJ-UHFFFAOYSA-N 0.000 description 2
- WPPHQMLVJQSSHR-UHFFFAOYSA-N ethyl 4-methyl-2-oxo-7-(trifluoromethyl)-1h-quinoline-3-carboxylate Chemical compound C1=C(C(F)(F)F)C=CC2=C(C)C(C(=O)OCC)=C(O)N=C21 WPPHQMLVJQSSHR-UHFFFAOYSA-N 0.000 description 2
- ZMJQYYLDCOWPJV-UHFFFAOYSA-N ethyl 6,7-difluoro-4-methyl-2-oxo-1h-quinoline-3-carboxylate Chemical compound C1=C(F)C(F)=CC2=C(C)C(C(=O)OCC)=C(O)N=C21 ZMJQYYLDCOWPJV-UHFFFAOYSA-N 0.000 description 2
- HYPAKOIHPRJOAL-UHFFFAOYSA-N ethyl 7-tert-butyl-2-ethylsulfanyl-4-methylquinoline-3-carboxylate Chemical compound C1=C(C(C)(C)C)C=C2N=C(SCC)C(C(=O)OCC)=C(C)C2=C1 HYPAKOIHPRJOAL-UHFFFAOYSA-N 0.000 description 2
- RKRFADVUFCAAIM-UHFFFAOYSA-N ethyl 7-tert-butyl-4-methyl-2-oxo-1h-quinoline-3-carboxylate Chemical compound C1=C(C(C)(C)C)C=CC2=C(C)C(C(=O)OCC)=C(O)N=C21 RKRFADVUFCAAIM-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LDTLDBDUBGAEDT-UHFFFAOYSA-N methyl 3-sulfanylpropanoate Chemical compound COC(=O)CCS LDTLDBDUBGAEDT-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- SUVIGLJNEAMWEG-UHFFFAOYSA-N propane-1-thiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 description 2
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960003312 retigabine Drugs 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical compound NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- QVSVMNXRLWSNGS-UHFFFAOYSA-N (3-fluorophenyl)methanamine Chemical compound NCC1=CC=CC(F)=C1 QVSVMNXRLWSNGS-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CTGQOICFEKCNSV-UHFFFAOYSA-N 1-(2-amino-4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1N CTGQOICFEKCNSV-UHFFFAOYSA-N 0.000 description 1
- PEIHHQGZBIZTPZ-UHFFFAOYSA-N 1-(2-amino-4-tert-butylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(C(C)(C)C)C=C1N PEIHHQGZBIZTPZ-UHFFFAOYSA-N 0.000 description 1
- YUZZZNBYRRMSPV-UHFFFAOYSA-N 1-(2-chloroethylsulfonyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)CCCl)=C1 YUZZZNBYRRMSPV-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- KEUIMKZBROFROK-UHFFFAOYSA-N 1-ethylsulfanyl-n-[3-(trifluoromethyl)phenyl]methanimidoyl chloride Chemical compound CCSC(Cl)=NC1=CC=CC(C(F)(F)F)=C1 KEUIMKZBROFROK-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- FFFIRKXTFQCCKJ-UHFFFAOYSA-N 2,4,6-trimethylbenzoic acid Chemical compound CC1=CC(C)=C(C(O)=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KAOSZKNBYIXONV-UHFFFAOYSA-N 2-chloro-4-methyl-7-(trifluoromethyl)quinoline-3-carbonyl chloride Chemical compound FC(F)(F)C1=CC=C2C(C)=C(C(Cl)=O)C(Cl)=NC2=C1 KAOSZKNBYIXONV-UHFFFAOYSA-N 0.000 description 1
- ARKUVZWWEQHTDG-UHFFFAOYSA-N 2-chloro-6-(trifluoromethyl)quinoline Chemical compound N1=C(Cl)C=CC2=CC(C(F)(F)F)=CC=C21 ARKUVZWWEQHTDG-UHFFFAOYSA-N 0.000 description 1
- MHKKTHDUBAZOQU-UHFFFAOYSA-N 2-ethylsulfanyl-7-fluoro-4-methylquinoline Chemical compound C1=CC(F)=CC2=NC(SCC)=CC(C)=C21 MHKKTHDUBAZOQU-UHFFFAOYSA-N 0.000 description 1
- RCQCMAMXXGCBIL-UHFFFAOYSA-N 2-ethylsulfanyl-7-fluoro-4-methylquinoline-3-carboxylic acid Chemical compound C(C)SC1=NC2=CC(=CC=C2C(=C1C(=O)O)C)F RCQCMAMXXGCBIL-UHFFFAOYSA-N 0.000 description 1
- DVPBKUXQKWCOCX-UHFFFAOYSA-N 2-ethylsulfanyl-7-fluoro-n-[(3-fluorophenyl)methyl]-4-methylquinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 DVPBKUXQKWCOCX-UHFFFAOYSA-N 0.000 description 1
- HKQCRHMWJQDOCL-UHFFFAOYSA-N 2-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-4-methyl-7-(trifluoromethoxy)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(OC(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(F)C=C1 HKQCRHMWJQDOCL-UHFFFAOYSA-N 0.000 description 1
- VIKBNMWOLLIQPG-UHFFFAOYSA-N 2-methyldecanedioic acid Chemical compound OC(=O)C(C)CCCCCCCC(O)=O VIKBNMWOLLIQPG-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VSXMSYVKRKWKDG-UHFFFAOYSA-N 3-ethyl-1,2-oxazol-5-amine Chemical compound CCC=1C=C(N)ON=1 VSXMSYVKRKWKDG-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SZHYDMKTGVCFLS-UHFFFAOYSA-N 4-(dimethylamino)-2-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(N(C)C)=C1C(=O)NCC1=CC=CC(F)=C1 SZHYDMKTGVCFLS-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- ILNJBIQQAIIMEY-UHFFFAOYSA-N 4-oxo-1h-quinoline-3-carboxylic acid Chemical class C1=CC=CC2=C(O)C(C(=O)O)=CN=C21 ILNJBIQQAIIMEY-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- VHODJNPZDUOZMO-UHFFFAOYSA-N 6,7-difluoro-4-methyl-2-oxo-1H-quinoline-3-carboxylic acid Chemical compound FC=1C=C2C(=C(C(=NC2=CC1F)O)C(=O)O)C VHODJNPZDUOZMO-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- MTPXDHMYHCMSAC-UHFFFAOYSA-N C(C)OC(=O)C=1C(=NC2=CC(=CC=C2C1C)C(C)(C)C)SCC.C(C)(C)(C)C1=CC=C2C(=C(C(=NC2=C1)SCC)C(=O)O)C Chemical compound C(C)OC(=O)C=1C(=NC2=CC(=CC=C2C1C)C(C)(C)C)SCC.C(C)(C)(C)C1=CC=C2C(=C(C(=NC2=C1)SCC)C(=O)O)C MTPXDHMYHCMSAC-UHFFFAOYSA-N 0.000 description 1
- KDOWJWHLIDPEDD-UHFFFAOYSA-N C(C)OC(CC(=O)NC1=C(C=CC(=C1)C(C)(C)C)C(C)=O)=O.C(C)OC(=O)C=1C(=NC2=CC(=CC=C2C1C)C(C)(C)C)O Chemical compound C(C)OC(CC(=O)NC1=C(C=CC(=C1)C(C)(C)C)C(C)=O)=O.C(C)OC(=O)C=1C(=NC2=CC(=CC=C2C1C)C(C)(C)C)O KDOWJWHLIDPEDD-UHFFFAOYSA-N 0.000 description 1
- ZFNZJMMXQYIGBJ-UHFFFAOYSA-M C(C)SC1=NC2=CC(=CC=C2C(=C1C(=O)[O-])C)C(F)(F)F.[Na+] Chemical compound C(C)SC1=NC2=CC(=CC=C2C(=C1C(=O)[O-])C)C(F)(F)F.[Na+] ZFNZJMMXQYIGBJ-UHFFFAOYSA-M 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- QIFGLANVCBUKES-UHFFFAOYSA-N ClC1=NC2=CC=C(C=C2C=C1C(=O)O)C(F)(F)F.C1(=CC=CC=C1)S(=O)(=O)CCSC1=NC2=CC=C(C=C2C=C1C(=O)O)C(F)(F)F Chemical compound ClC1=NC2=CC=C(C=C2C=C1C(=O)O)C(F)(F)F.C1(=CC=CC=C1)S(=O)(=O)CCSC1=NC2=CC=C(C=C2C=C1C(=O)O)C(F)(F)F QIFGLANVCBUKES-UHFFFAOYSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- CJQWLNNCQIHKHP-UHFFFAOYSA-N Ethyl 3-mercaptopropanoic acid Chemical compound CCOC(=O)CCS CJQWLNNCQIHKHP-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- 101000994648 Homo sapiens Potassium voltage-gated channel subfamily KQT member 4 Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 108010038888 KCNQ3 Potassium Channel Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 description 1
- 102100034360 Potassium voltage-gated channel subfamily KQT member 3 Human genes 0.000 description 1
- 102100034363 Potassium voltage-gated channel subfamily KQT member 4 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- HMHDTKVDYSBADJ-UHFFFAOYSA-N S(=O)(Cl)Cl.ClC1=NC2=CC=CC=C2C=C1C(=O)O Chemical compound S(=O)(Cl)Cl.ClC1=NC2=CC=CC=C2C=C1C(=O)O HMHDTKVDYSBADJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- VBIZJDVCBYIYMR-UHFFFAOYSA-N ethyl 2-chloro-4-methyl-7-(trifluoromethyl)quinoline-3-carboxylate 4-methyl-2-oxo-7-(trifluoromethyl)-1H-quinoline-3-carboxylic acid Chemical compound OC1=NC2=CC(=CC=C2C(=C1C(=O)O)C)C(F)(F)F.C(C)OC(=O)C=1C(=NC2=CC(=CC=C2C1C)C(F)(F)F)Cl VBIZJDVCBYIYMR-UHFFFAOYSA-N 0.000 description 1
- CSRYVZCBXNSWGH-UHFFFAOYSA-N ethyl 2-ethylsulfanyl-4-methyl-7-(trifluoromethoxy)quinoline-3-carboxylate Chemical compound C1=C(OC(F)(F)F)C=C2N=C(SCC)C(C(=O)OCC)=C(C)C2=C1 CSRYVZCBXNSWGH-UHFFFAOYSA-N 0.000 description 1
- MHKCQVJDUCPPMM-UHFFFAOYSA-N ethyl 2-ethylsulfanyl-7-fluoro-4-methylquinoline-3-carboxylate Chemical compound C1=C(F)C=C2N=C(SCC)C(C(=O)OCC)=C(C)C2=C1 MHKCQVJDUCPPMM-UHFFFAOYSA-N 0.000 description 1
- ZJRBFSCAJFDUEJ-UHFFFAOYSA-N ethyl 3-(2-acetyl-5-tert-butylanilino)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NC1=CC(C(C)(C)C)=CC=C1C(C)=O ZJRBFSCAJFDUEJ-UHFFFAOYSA-N 0.000 description 1
- KWFADUNOPOSMIJ-UHFFFAOYSA-N ethyl 3-chloro-3-oxopropanoate Chemical compound CCOC(=O)CC(Cl)=O KWFADUNOPOSMIJ-UHFFFAOYSA-N 0.000 description 1
- 125000006437 ethyl cyclopropyl group Chemical group 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- FYAQQULBLMNGAH-UHFFFAOYSA-N hexane-1-sulfonic acid Chemical compound CCCCCCS(O)(=O)=O FYAQQULBLMNGAH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 102000053004 human KCNQ2 Human genes 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- XISAPBZGVIHRHA-UHFFFAOYSA-N n-(2-acetyl-5-tert-butylphenyl)propanamide Chemical compound CCC(=O)NC1=CC(C(C)(C)C)=CC=C1C(C)=O XISAPBZGVIHRHA-UHFFFAOYSA-N 0.000 description 1
- SIBOZKOCLHAEOC-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-2-propylsulfanyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=CC(F)=C1 SIBOZKOCLHAEOC-UHFFFAOYSA-N 0.000 description 1
- ZQIVOMOWMDUEDS-UHFFFAOYSA-N n-[(5-chlorothiophen-2-yl)methyl]-2-ethylsulfanyl-4-methyl-7-(trifluoromethyl)quinoline-3-carboxamide Chemical compound CCSC1=NC2=CC(C(F)(F)F)=CC=C2C(C)=C1C(=O)NCC1=CC=C(Cl)S1 ZQIVOMOWMDUEDS-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- HNUSZIQSLZBZTO-UHFFFAOYSA-N quinoline-3-carbonyl chloride Chemical compound C1=CC=CC2=CC(C(=O)Cl)=CN=C21 HNUSZIQSLZBZTO-UHFFFAOYSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09003597.3 | 2009-03-12 | ||
| EP09003597 | 2009-03-12 | ||
| PCT/EP2010/001509 WO2010102811A1 (de) | 2009-03-12 | 2010-03-11 | Substituierte 2-mercaptochinolin-3-carboxamide als kcnq2/3 modulatoren |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012520249A JP2012520249A (ja) | 2012-09-06 |
| JP2012520249A5 JP2012520249A5 (cg-RX-API-DMAC7.html) | 2014-10-16 |
| JP5727946B2 true JP5727946B2 (ja) | 2015-06-03 |
Family
ID=40671387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553352A Expired - Fee Related JP5727946B2 (ja) | 2009-03-12 | 2010-03-11 | Ｋｃｎｑ２／３モジュレータとしての置換された２−メルカプトキノリン−３−カルボキサミド |
Country Status (20)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3178067B2 (ja) | 1991-02-26 | 2001-06-18 | ぺんてる株式会社 | スズ−ニッケル二元合金電気めっき液組成物 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012520246A (ja) * | 2009-03-10 | 2012-09-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｋｃｎｑ２／３モジュレータとしての置換された３−アミノイソオキサゾロピリジン |
| TWI504395B (zh) * | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
| TWI475020B (zh) | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| TW201038565A (en) | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
| DK2609083T3 (da) | 2010-08-27 | 2015-03-30 | Gruenenthal Gmbh | Substituerede 2-oxy-quinolin-3-carboxamider som KCNQ2/3 modulatorer |
| WO2012025239A1 (en) | 2010-08-27 | 2012-03-01 | Grünenthal GmbH | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators |
| MX2013002295A (es) | 2010-09-01 | 2013-05-09 | Gruenenthal Gmbh | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. |
| CN104994857A (zh) | 2012-10-11 | 2015-10-21 | 格吕伦塔尔有限公司 | Tspo介导的疾病和/或障碍的治疗和/或预防 |
| EP2951156A1 (en) * | 2012-11-28 | 2015-12-09 | Grünenthal GmbH | Specific carboxamides as kcnq2/3 modulators |
| US9248122B2 (en) | 2012-11-28 | 2016-02-02 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as KCNQ2/3 modulators |
| EP2925759A1 (en) | 2012-11-28 | 2015-10-07 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as kcnq2/3 modulators |
| AR095192A1 (es) * | 2013-01-31 | 2015-09-30 | Vertex Pharma | Quinolina y quinazolinamidas como modulares de canales de sodio |
| JP2016511237A (ja) | 2013-02-01 | 2016-04-14 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 選択的ｈｄａｃ３阻害剤 |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| HK1217092A1 (zh) | 2013-02-15 | 2016-12-23 | Kala Pharmaceuticals, Inc. | 治疗性化合物及其用途 |
| ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| PH12015000236B1 (en) * | 2015-07-06 | 2024-01-10 | Samsung Electronics Co Ltd | Electronic device for providing a calibrated keyboard configuration |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR20190051010A (ko) | 2016-09-08 | 2019-05-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정형 및 그의 용도 |
| JP7120549B2 (ja) * | 2016-12-15 | 2022-08-17 | 小野薬品工業株式会社 | Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ |
| DE102018212006B3 (de) | 2018-07-18 | 2019-10-31 | Universität Greifswald | Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen |
| EP4580618A2 (en) * | 2022-08-30 | 2025-07-09 | Pannex Therapeutics Inc. | Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2706977A1 (de) | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
| FR2532939A1 (fr) * | 1982-09-13 | 1984-03-16 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus |
| DE4032147A1 (de) | 1990-10-10 | 1992-04-16 | Bayer Ag | Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung |
| EP0716077A1 (de) | 1994-12-08 | 1996-06-12 | Ciba-Geigy Ag | Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren |
| WO1996026925A1 (en) | 1995-03-01 | 1996-09-06 | Banyu Pharmaceutical Co., Ltd. | Arylthioacetamide derivatives |
| DE19738616A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel |
| DE19738615A1 (de) * | 1997-09-04 | 1999-03-11 | Clariant Gmbh | Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen |
| AU3033500A (en) * | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| NZ527771A (en) | 1999-08-04 | 2005-04-29 | Icagen Inc | Methods for treating or preventing anxiety |
| WO2001010380A2 (en) | 1999-08-04 | 2001-02-15 | Icagen, Inc. | Benzanilides as potassium channel openers |
| EP1441722A2 (en) * | 2001-02-20 | 2004-08-04 | Bristol-Myers Squibb Company | Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases |
| CA2438231A1 (en) | 2001-02-20 | 2002-08-29 | Gene G. Kinney | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
| US6593349B2 (en) | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| EP1372654A4 (en) * | 2001-04-06 | 2007-10-03 | Smithkline Beecham Corp | QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES |
| BR0314390A (pt) | 2002-09-17 | 2005-07-19 | Pharmacia Corp | Moduladores aromáticos dos receptores hepáticos x |
| AU2003303484C1 (en) | 2002-12-23 | 2012-06-14 | Icagen, Inc. | Quinazolinones as potassium channel modulators |
| EP1449841A1 (en) | 2003-02-19 | 2004-08-25 | Bayer CropScience SA | New fungicidal compounds |
| KR20060121909A (ko) | 2003-10-08 | 2006-11-29 | 버텍스 파마슈티칼스 인코포레이티드 | 사이클로알킬 또는 피라닐 그룹을 포함하는 ａｔｐ-결합카세트 수송자의 조절자 |
| AP2006003769A0 (en) | 2004-05-04 | 2006-10-31 | Pfizer | Ortho substituted aryl or heteroaryl amide compounds |
| BR122018075478B8 (pt) * | 2004-06-24 | 2023-10-31 | Vertex Pharma | moduladores de transportadores de cassete de ligação de atp |
| JP2008519814A (ja) | 2004-11-12 | 2008-06-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物 |
| AU2006220130B2 (en) | 2005-03-03 | 2011-07-28 | H. Lundbeck A/S | Substituted pyridine derivatives |
| DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| WO2007015767A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | Pyridine derivatives as dipeptedyl peptidase inhibitors |
| EP1922311A2 (en) | 2005-09-09 | 2008-05-21 | Brystol-Myers Squibb Company | Acyclic ikur inhibitors |
| WO2007057447A1 (en) | 2005-11-18 | 2007-05-24 | Neurosearch A/S | Novel quinazoline derivatives and their medical use |
| EP2057133B1 (en) | 2006-07-20 | 2014-08-20 | Amgen Inc. | Di-amino-substituted heterocyclic compounds and methods of use |
| DE602007004638D1 (de) | 2006-07-20 | 2010-03-18 | Amgen Inc | Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin |
| US20100022589A1 (en) | 2006-07-27 | 2010-01-28 | Mccoull William | Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
| DE102006049452A1 (de) | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
| CA2670966A1 (en) * | 2006-11-28 | 2008-06-05 | Valeant Pharmaceuticals International | 1,4 diamino bicyclic retigabine analogues as potassium channel modulators |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| BRPI0814758A2 (pt) | 2007-08-03 | 2015-03-03 | Hoffmann La Roche | Piridinacarboxamida e derivados de benzamida como ligantes taar1 |
| WO2009052078A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Ccr10 antagonists |
| JP2012520246A (ja) * | 2009-03-10 | 2012-09-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｋｃｎｑ２／３モジュレータとしての置換された３−アミノイソオキサゾロピリジン |
| TWI504395B (zh) * | 2009-03-10 | 2015-10-21 | Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier | |
| TWI475020B (zh) * | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| TW201038565A (en) * | 2009-03-12 | 2010-11-01 | Gruenenthal Gmbh | Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators |
-
2010
- 2010-02-24 TW TW099105238A patent/TWI461197B/zh not_active IP Right Cessation
- 2010-03-10 US US12/720,864 patent/US20100234372A1/en not_active Abandoned
- 2010-03-11 PE PE2011001567A patent/PE20120790A1/es not_active Application Discontinuation
- 2010-03-11 EP EP10708726A patent/EP2406229A1/de not_active Withdrawn
- 2010-03-11 CA CA2755004A patent/CA2755004A1/en not_active Abandoned
- 2010-03-11 CN CN2010800112967A patent/CN102348692A/zh active Pending
- 2010-03-11 KR KR1020117023788A patent/KR20110132590A/ko not_active Withdrawn
- 2010-03-11 MX MX2011009369A patent/MX2011009369A/es active IP Right Grant
- 2010-03-11 NZ NZ595625A patent/NZ595625A/xx not_active IP Right Cessation
- 2010-03-11 WO PCT/EP2010/001509 patent/WO2010102811A1/de not_active Ceased
- 2010-03-11 AU AU2010223513A patent/AU2010223513B2/en not_active Ceased
- 2010-03-11 JP JP2011553352A patent/JP5727946B2/ja not_active Expired - Fee Related
- 2010-03-11 BR BRPI1008939A patent/BRPI1008939A2/pt not_active IP Right Cessation
- 2010-03-11 RU RU2011141188/04A patent/RU2011141188A/ru not_active Application Discontinuation
- 2010-03-12 AR ARP100100777A patent/AR075824A1/es not_active Application Discontinuation
-
2011
- 2011-08-24 CO CO11107978A patent/CO6410292A2/es not_active Application Discontinuation
- 2011-09-04 IL IL214945A patent/IL214945A0/en unknown
- 2011-09-08 CL CL2011002209A patent/CL2011002209A1/es unknown
- 2011-09-23 EC EC2011011348A patent/ECSP11011348A/es unknown
- 2011-10-11 ZA ZA2011/07444A patent/ZA201107444B/en unknown
-
2012
- 2012-06-15 US US13/523,955 patent/US8399673B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3178067B2 (ja) | 1991-02-26 | 2001-06-18 | ぺんてる株式会社 | スズ−ニッケル二元合金電気めっき液組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL214945A0 (en) | 2011-11-30 |
| AU2010223513B2 (en) | 2014-12-04 |
| WO2010102811A1 (de) | 2010-09-16 |
| US20100234372A1 (en) | 2010-09-16 |
| RU2011141188A (ru) | 2013-04-20 |
| NZ595625A (en) | 2012-10-26 |
| CL2011002209A1 (es) | 2012-02-10 |
| PE20120790A1 (es) | 2012-07-08 |
| US8399673B2 (en) | 2013-03-19 |
| CA2755004A1 (en) | 2010-09-16 |
| AU2010223513A1 (en) | 2011-11-03 |
| EP2406229A1 (de) | 2012-01-18 |
| TWI461197B (zh) | 2014-11-21 |
| CN102348692A (zh) | 2012-02-08 |
| JP2012520249A (ja) | 2012-09-06 |
| AR075824A1 (es) | 2011-04-27 |
| BRPI1008939A2 (pt) | 2016-03-15 |
| ECSP11011348A (es) | 2011-10-31 |
| MX2011009369A (es) | 2011-09-27 |
| CO6410292A2 (es) | 2012-03-30 |
| TW201034670A (en) | 2010-10-01 |
| ZA201107444B (en) | 2012-06-27 |
| KR20110132590A (ko) | 2011-12-08 |
| US20120252841A1 (en) | 2012-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5727946B2 (ja) | Ｋｃｎｑ２／３モジュレータとしての置換された２−メルカプトキノリン−３−カルボキサミド | |
| JP5670359B2 (ja) | Ｋｃｎｑ２／３モジュレータとしての置換されたニコチンアミド | |
| JP5727945B2 (ja) | Ｋｃｎｑ２／３モジュレータとしての置換された３−アミノ−２−メルカプトキノリン | |
| JP5583148B2 (ja) | Ｋｃｎｑ２／３モジュレータとしての置換された２−メルカプト−アミノピリジン | |
| JP2012512214A (ja) | Ｋｃｎｑ２／３モジュレータとしての置換された４−（１，２，３，４−テトラヒドロイソキノリン−２−イル）−４−オキソ−酪酸アミド | |
| JP2012520246A (ja) | Ｋｃｎｑ２／３モジュレータとしての置換された３−アミノイソオキサゾロピリジン | |
| TWI522349B (zh) | 作為ｋｃｎｑ２／３調節劑之被取代之２－氧基－喹啉－３－甲醯胺 | |
| EP2609085A1 (en) | Substituted quinoline-3-carboxamides as kcnq2/3 modulators | |
| US8653102B2 (en) | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140610 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20140901 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140902 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150325 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150403 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5727946 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |